FHTX 외환 뉴스
Foghorn Therapeutics Says FDA Places Clinical Hold On Phase 1 Dose Escalation Study Of FHD-286
Biotechnology company Foghorn Therapeutics Inc. (FHTX) announced Tuesday that the U.S. Food and Drug Administration (FDA) has placed a full clinical hold on the Phase 1 dose escalation study of FHD-286, an inhibitor of BRG1/BRM, in relapsed and/or refractory acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS).
RTTNews
|
871 일 전
